Komodo Health AI
Komodo Health / komodohealth.com
AI-powered healthcare analytics platform providing real-world evidence from longitudinal patient journey data across 330 million patients for pharmaceutical market access, clinical research, and population health management.
Pricing
Free
Free plan
No
Category
Developer Tools
Platforms
2
Free plan
No
API access
No
Open source
No
Platforms
2
Advertisement
What is Komodo Health AI?
Komodo Health is a real-world health data analytics company built around the Healthcare Map — a longitudinal database of patient journeys covering 330 million US patients, integrating claims, lab results, electronic health records, and specialty pharmacy data into a unified patient-level dataset.
Komodo's AI analytics apply machine learning to this dataset to generate real-world evidence for pharmaceutical companies (market access submissions, clinical trial design, patient identification), health systems (population health management, quality improvement), and payers (value-based care analytics).
Patient identification and site of care analytics help pharmaceutical companies find patients with specific diagnoses, on specific treatment journeys, or responding to specific therapies — enabling targeted patient support programmes, clinical trial recruitment, and market access evidence.
Treatment journey analytics reveal actual prescribing patterns, switching behaviour, time-to-treatment, and discontinuation rates across patient populations — informing pharmaceutical marketing strategy and patient support programme design with real-world evidence that clinical trial data cannot provide.
Komodo's Pulse platform makes the Healthcare Map accessible through a SaaS analytics interface rather than requiring each client to build custom database queries — enabling pharmaceutical and healthcare analytics teams to access real-world evidence through self-service workflows.
How Komodo Health AI works
Komodo Health AI runs as ml platform software built around data workflows. Users typically start with a prompt, upload, or connected data source, and the underlying model handles the heavy lifting before returning a result you can refine or export. It's available on web and api.
Watch Komodo Health AI in action
Recent YouTube videos cached from the backend so this page stays fast and fresh.
What makes it worth shortlisting
The capabilities that matter most for teams evaluating Komodo Health AI.
Healthcare Map
330 million patient longitudinal database integrating claims, lab results, EHR, and specialty pharmacy data for comprehensive US real-world patient journey evidence.
Treatment journey analytics
AI analysis of actual prescribing patterns, treatment switching, time-to-treatment, and discontinuation rates from real-world patient data — informing pharmaceutical strategy with evidence clinical trials cannot provide.
Patient identification
AI identification of patients with specific diagnoses, on specific treatment journeys, or eligible for clinical trials — enabling targeted patient support and research recruitment from real-world data.
Best use cases
Who should use it
Pros
- 330 million patient longitudinal data coverage is one of the most comprehensive US real-world health datasets
- Integrated claims, lab, and EHR data provides richer patient journey evidence than single-source datasets
- Pulse SaaS interface makes real-world evidence accessible without custom database development
- Pharmaceutical market access teams can generate regulatory-grade evidence from real-world data
Cons
- Enterprise-only licensing appropriate for pharmaceutical companies and large health systems with analytics budgets
- Real-world data has limitations — claims-based patient identification is less accurate than clinical data
- Regulatory acceptance of real-world evidence varies by market and indication — not a substitute for clinical trials
Advertisement
Is it worth the price?
Enterprise licensing to pharmaceutical companies, health systems, and payers. No public pricing. Contact for pricing.
Model
Enterprise
Starting price
Free
Free trial
No
Tools like Komodo Health AI
IQVIA provides competing real-world data at similar enterprise scale. Flatiron Health (covered) focuses on oncology real-world data. Symphony Health provides pharmaceutical real-world data analytics. Inovalon provides healthcare data analytics.
Komodo Health AI vs Flatiron Health AI
A side-by-side look at the closest alternative in this category.
Komodo Health AI
Komodo Health
Flatiron Health AI
Flatiron Health (Roche)
Enterprise licensing to pharmaceutical companies, health systems, and payers. No public pricing. Contact for pricing.
Enterprise licensing to pharmaceutical companies and cancer centres. No public pricing. Subsidiary of Roche.
HIPAA compliant with BAA. SOC 2 Type II. IRB approval for research datasets. De-identification standards. Enterprise data handling agreements.
HIPAA compliant with BAA. SOC 2 Type II. GDPR compliant for EU deployments. IRB approval for research datasets. FDA-accepted data quality standards.
Patient health data de-identified under HIPAA de-identification standards. Access requires data use agreements and IRB approval for research purposes. Review Komodo's data governance framework.
Patient health data processed under strict HIPAA BAA and applicable research ethics frameworks. De-identification and IRB protocols govern research dataset access.
- 330 million patient longitudinal data coverage is one of the most comprehensive US real-world health datasets
- Integrated claims, lab, and EHR data provides richer patient journey evidence than single-source datasets
- Pulse SaaS interface makes real-world evidence accessible without custom database development
- Pharmaceutical market access teams can generate regulatory-grade evidence from real-world data
- 9 million+ patient oncology database is one of the most comprehensive real-world oncology datasets available for pharmaceutical research
- FDA-accepted real-world evidence from multiple regulatory submissions provides unmatched regulatory validation
- NLP curation of clinical notes extracts structured data inaccessible through structured EHR data alone
- Roche ownership provides stability and pharmaceutical partnership pipeline
- Enterprise-only licensing appropriate for pharmaceutical companies and large health systems with analytics budgets
- Real-world data has limitations — claims-based patient identification is less accurate than clinical data
- Regulatory acceptance of real-world evidence varies by market and indication — not a substitute for clinical trials
- Roche ownership creates potential conflict of interest concerns for pharmaceutical competitors as data partners
- Real-world evidence database access requires partnership agreements limiting accessibility
- Clinical note NLP accuracy requires ongoing validation — structured EHR data remains more reliable for some variables
Technical & deployment info
Key facts about model providers, platforms, and team support.
Model Provider
Komodo Health
Platforms
Web, API
Deployment
SaaS
Integrations
EHR systems, Specialty pharmacy data, Claims data, API
Team Collaboration
No
Launch Year
2021
Security & privacy
Compliance signals and data-handling notes as reported by the vendor.
HIPAA compliant with BAA. SOC 2 Type II. IRB approval for research datasets. De-identification standards. Enterprise data handling agreements.
Patient health data de-identified under HIPAA de-identification standards. Access requires data use agreements and IRB approval for research purposes. Review Komodo's data governance framework.
What users are saying
Verified reviews from signed-in users, stored in the backend and averaged into this tool's rating.
Sign in to rate Komodo Health AI and leave a review.
No other reviews yet — be the first to share how this tool performs in practice.
Common questions about Komodo Health AI
Editorial Verdict
Should you use Komodo Health AI?
Komodo Health is the leading AI real-world health data platform for pharmaceutical companies and health systems wanting real-world evidence from longitudinal patient journey data across 330 million US patients.
Last verified July 24, 2026.